The medicine created in the Russian Federation has passed clinical trials as a remedy for tick-borne encephalitis

Antiviral drug triazavirin was developed by researchers of the Ural Branch of the Russian Academy of Sciences and the Ural Federal University.

Employees of the Krasnoyarsk State Medical University conducted clinical trials of antiviral drug triazavirin, developed by Ural researchers, and confirmed its effectiveness for tick-borne viral encephalitis (EEC). It was reported by the press service of the Ministry of Science and Higher Education of the Russian Federation.

According to statistics, the Krasnoyarsk Territory is considered the largest natural foci of tick-borne encephalitis in Russia. Over the past years, the incidence in the region has exceeded the average Russian indicators by 9.5 times. Despite the use of specific antiviral and immunotropic drugs, such as RNA-aza, ribavirin, panavir, ferrovir, new cases of disability and death of inhabitants of the region infected with encephalitis are recorded annually.

“Triazavirin, developed by researchers of the Ural Branch of the Russian Academy of Sciences (Ural Branch of the Russian Academy of Sciences) and the Ural Federal University (Ural Federal University, Yekaterinburg), proved to be an effective remedy against tick-borne encephalitis (EHE). Clinical trials conducted by Krasnoyarsk State Medical University “- said in a statement.

In search of effective treatments for tick-borne viral encephalitis, university staff decided to study the properties of triazavirin. This drug, which has been developed since the late 1980s, entered the pharmacy chain in 2014 and proved itself as a powerful tool against influenza viruses (including avian and swine), bronchial asthma, and also rubella, measles, and herpes. In addition, triazavirin has been shown to be effective against Ebola virus, Marburg hemorrhagic fever, and West Nile fever. The main mechanism of drug action is the blockade of viral RNA synthesis.

The study, conducted in the Krasnoyarsk Interdistrict Clinical Emergency Hospital, involved 73 patients with febrile forms of tick-borne viral encephalitis. The inclusion of triazavirin in the treatment regimen, as the scientists note, was accompanied by a decrease in all clinical manifestations of this disease: fever stopped by 2.3 times, intoxication syndrome by 1.8 times, catarrhal phenomena by 1.7 times faster.

“The results of the study allow us to assign triazavirin, taking into account the mechanism of its action in tick-borne viral encephalitis, to the group of etiotropic agents with good efficacy and tolerability,” the report says. In addition to the Krasnoyarsk Territory, the drug may be in demand in other regions – in the Urals, in Western and Eastern Siberia, where tick-borne encephalitis is an endemic disease.